• BioMarin Pharmaceutical Inc., of Novato, Calif., said it started a Phase I study in healthy volunteers for BMN-111, an analogue of C-type natriuretic peptide in development for achondroplasia. The trial is a two-part study designed to test single and multiple subcutaneous doses of the drug in up to 74 subjects. Data are expected in the third quarter of this year.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter